GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
June 28, 2016 7:58 AM EDT
Morgan Stanley maintained an Overweight rating on GW Pharma (NASDAQ: GWPH) and raised its price target to $152.00 (from $149.00).
For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.
Shares of GW Pharma closed at $88.49 yesterday.
...
More
June 27, 2016 9:52 AM EDT
Leerink Partners analyst Paul Matteis reiterated an Outperform rating and raised his price target on GW Pharma (NASDAQ: GWPH) to $138.00 (from $130.00) after the company announced positive results for its 1st Phase 3 study for Epidiolex in Lennox-Gastaut Syndrome (LGS).
"... our view remains positive after the... More
June 27, 2016 7:42 AM EDT
Leerink Partners analyst Paul Matteis offered some initial thoughts on GW Pharma (NASDAQ: GWPH) after the company announced positive top-line results for Epidiolex in Lennox Gastaut Syndrome (LGS).
Matteis commented, "The data show a 22% seizure reduction relative to placebo, suggesting that Epidiolex's... More
